Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin
- 31 October 1991
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 14 (1) , 47-54
- https://doi.org/10.1016/0168-8227(91)90052-f
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administrationActa Endocrinologica, 1986
- Overview of the association between insulin and atherosclerosisMetabolism, 1985
- The Role of Insulin in Atherosclerosis in Diabetics and Nondiabetics: A ReviewDiabetes, 1981
- Effects of Somatostatin on Gastrointestinal Propagation and Absorption of Oral Glucose in ManDigestion, 1980
- Metabolic Clearance and Plasma Half-Disappearance Time of Exogenous Somatostatin in Man*Journal of Clinical Endocrinology & Metabolism, 1979
- Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitusDiabetologia, 1977
- Oral Hypoglycaemic DrugsDrugs, 1977
- INFLUENCE OF SOMATOSTATIN ON CARBOHYDRATE DISPOSAL AND ABSORPTION IN DIABETES MELLITUSThe Lancet, 1976
- The Inhibitory Effect of Somatostatin on Growth Hormone, Insulin and Glucagon Secretion in Diabetes Mellitus1Journal of Clinical Endocrinology & Metabolism, 1975
- Effects of Somatostatin on Plasma Glucose and Glucagon Levels in Human Diabetes MellitusNew England Journal of Medicine, 1974